ESMO 2024 Archives

CodeBreaK 101: preliminary results show promise of KRAS G12C inhibitor in the first-line setting for patients with metastatic colorectal cancer

Presented at ESMO Congress 2024, results from the phase 1b CodeBreaK study in patients with KRAS G12C-mutated metastatic colorectal cancer…

Investigational antibody-drug conjugate shows promising efficacy in patients with advanced endometrial or ovarian cancer

The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…

ESMO Congress 2024: progresses in delivering precision oncology to patients with advanced solid tumors

Advances driven by research have led to significant developments in better understanding the molecular taxonomy of cancer and therapeutic breakthroughs…

Follow-up from the POSITIVE study: latest results suggest that breastfeeding in women with hormone receptor-positive early breast cancer is possible and does not impact on prognosis

Among the 518 women enrolled in the international POSITIVE clinical trial with hormone receptor-positive early breast cancer who temporarily interrupted…